Howard Robin Sells NKTR Shares Valued at Over $600K

On June 17, 2026, Howard Robin, the President and CEO of NKTR, sold 10,000 shares in a planned transaction. The shares were sold at an average price of $61.19, resulting in a total transaction value of approximately $611,880. This sale was part of a scheduled plan.

Insider Buying and Selling at Nektar Therapeutics

Howard Robin has been actively selling shares over the past few months. On June 16, he sold another 10,000 shares at $60.32 each. Earlier, on May 19, he sold 444 shares at $65.51, and on February 18, he sold 423 shares at $73. Jonathan Zalevsky, the Chief R&D Officer, also sold shares, including 5,538 shares on June 15 at $60.71.

Other Institutional Activity in NKTR

Several major funds have adjusted their positions in NKTR. FMR LLC dramatically increased its holdings by 4,202,059 shares, ending with 4,303,188 shares valued at about $309.6 million. BVF INC/IL added 1,000,000 shares, bringing its total to 2,559,595 shares worth approximately $184.2 million. Two Seas Capital LP increased its stake by 1,213,993 shares to a total of 1,959,178 shares valued at around $141 million. Meanwhile, Vanguard Capital Management LLC added 1,197,055 shares to hold a total of 1,197,055 shares worth about $86.1 million.

Analysts Set New Price Targets

Analysts have been maintaining their ratings on NKTR. On May 11, 2026, Wedbush maintained a 'hold' rating with a target price of $80. Piper Sandler kept a 'buy' rating with a target of $192 on May 8. Citigroup also maintained a 'buy' rating, setting a target price of $151 on April 21. Overall, the consensus among analysts indicates a positive outlook, with a mean target price suggesting upside potential.

About NKTR

NKTR is a biopharmaceutical company specializing in the development of innovative therapies to treat chronic pain, cancer, and autoimmune diseases. The company is based in San Francisco, California, and is led by CEO Howard Robin. NKTR is known for its proprietary PEGylation technology, which enhances the pharmacokinetics of drugs, improving their efficacy and safety profiles.

Bottom Line

Howard Robin's recent sale of NKTR shares is part of a planned transaction and reflects ongoing insider activity. Investors often watch such transactions closely for insights into executive sentiment. While insider sales can raise questions, they are not necessarily indicative of future performance. NKTR continues to attract attention from institutional investors and analysts, with many maintaining positive ratings and price targets.